Evidence review
Tirzepatide Weight-Regain Evidence
The strongest evidence on weight regain after tirzepatide comes from SURMOUNT-4, a randomised withdrawal trial. After a 36-week lead-in on the maximum tolerated dose, participants who switched to placebo regained substantially over the following 52 weeks while those who continued maintained their loss. Regain reflects the return of appetite signalling once the drug is removed.
Key takeaways
- SURMOUNT-4 is randomised-withdrawal evidence, which is stronger than observational follow-up.
- Continuing treatment maintained loss; switching to placebo produced substantial regain.
- Regain is physiological — appetite signalling returns — rather than a behavioural failure.
- The pattern matches semaglutide withdrawal trials, suggesting a class effect.
- The practical consequence is financial: budget for sustained cost, not a short course.
| Primary evidence | SURMOUNT-4 (randomised withdrawal) |
|---|---|
| Design | 36-week open-label lead-in, then 52 weeks continue vs placebo |
| Participants | 670 |
| Finding | Substantial regain after withdrawal; maintenance with continued treatment |
| Identifiers | NCT04660643 · PMID 38078870 |
| Trial | Population | N | Result | Identifiers |
|---|---|---|---|---|
| SURMOUNT-4 | Adults with obesity or overweight, without type 2 diabetes | 670 | Continued treatment maintained and modestly extended weight loss; withdrawal to placebo produced substantial regain | NCT04660643 · PMID 38078870 · DOI |
Why does weight return after stopping?
Because the drug's effect is pharmacological, not educational. Tirzepatide acts on GIP and GLP-1 receptor pathways that reduce appetite and slow gastric emptying while it is present. Remove it and those signals return to baseline, appetite increases, and intake rises — usually without the person feeling that anything about their willpower has changed.
This is why framing regain as relapse or failure is both inaccurate and unhelpful. The trial evidence describes a predictable physiological response to withdrawal.
Is regain inevitable and total?
Not total, and not identical for everyone. SURMOUNT-4 reports group means over a fixed window; some participants regained faster than others and the trial did not run long enough to establish an endpoint. What the data does not support is the common marketing implication that a limited course produces a durable result.
- Trial windows are finite; very long-term regain trajectories are not established.
- Withdrawal trials cannot tell you which individuals will regain fastest.
- Findings describe the approved product; no compounded product has been studied this way.
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 56 | Wk 72 |
|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | 0% | -6.5% | -12.4% | -16.8% | -19.3% | -20.9% |
| Tirzepatide 5 mg | 0% | -5.1% | -9.3% | -12.4% | -14.2% | -15.0% |
| Placebo | 0% | -1.4% | -2.3% | -2.8% | -3.0% | -3.1% |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Withdrawal, follow-up, timing and variability and maintenance, organised around the primary question of tirzepatide weight regain study. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Withdrawal | Covered on this page | Primary evidence |
| Follow-up | Covered on this page | Primary evidence |
| Timing | Covered on this page | Primary evidence |
| Variability and maintenance | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with the registered protocol and the peer-reviewed publication |
What are the limits of what this page can tell you?
Every page on this site rests on a specific primary trial record, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the registered protocol and the peer-reviewed publication.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on tirzepatide weight regain study.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 11 technical terms this page uses, including DOI, GIP, GLP-1, PMID — in the specific sense used above.
| DOI | Digital Object Identifier. A persistent link to a specific published article that continues to resolve even if the journal reorganises its website. |
|---|---|
| GIP | Glucose-dependent insulinotropic polypeptide. An incretin hormone released by the small intestine after eating. Tirzepatide activates its receptor alongside the GLP-1 receptor, which is the feature that distinguishes it from single-agonist drugs such as semaglutide. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| PMID | PubMed Identifier. A number that locates the peer-reviewed publication of a study in the PubMed database. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| endpoint | The outcome a trial is designed to measure. A primary endpoint is specified before the trial begins; secondary and exploratory endpoints carry progressively weaker inferential weight. |
| gastric emptying | The rate at which food leaves the stomach. Incretin therapies slow it, which prolongs fullness and is also the mechanism behind much of the nausea and the perioperative aspiration concern. |
| maximum tolerated dose | The highest dose an individual can take without unacceptable adverse effects. Trials frequently escalate to this point rather than to a fixed dose, which means participants in one arm may be taking different amounts. |
| open-label | A trial in which participants and investigators know which treatment is being given. SURMOUNT-5 was open-label, a genuine limitation, though weight is an objective measurement less vulnerable to expectation than a self-reported outcome. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
| randomised withdrawal | A design in which everyone first receives the active drug, and only those who respond are then randomised to continue or stop. SURMOUNT-4 used this design, which is why its regain finding cannot be explained away by differences between groups. |
Frequently asked questions
Will I regain weight if I stop tirzepatide?
On average, substantial regain followed withdrawal in SURMOUNT-4. Individual results vary, but maintaining the loss generally requires continued treatment.
How fast does regain happen?
Regain accumulated over the 52-week randomised withdrawal period; the trial does not support a precise personal timeline.
Is regain a sign of failure?
No. It is a physiological response to removing a drug that suppresses appetite while present.
Can a lower maintenance dose prevent regain?
That is the question SURMOUNT-MAINTAIN was designed to test; results were published in the Lancet in 2026 yet.
Does this apply to compounded tirzepatide?
No compounded product has been studied in a withdrawal trial. Compounded tirzepatide is not FDA approved and is not reviewed by the FDA for safety, effectiveness, or quality before sale.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.